Published in Br J Clin Pharmacol on September 13, 2007
Inflammatory mechanisms in ischemic stroke: therapeutic approaches. J Transl Med (2009) 3.35
The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. J Neuroinflammation (2008) 2.03
Transport of interleukin-1 across cerebromicrovascular endothelial cells. Br J Pharmacol (2009) 1.12
Rapid brain penetration of interleukin-1 receptor antagonist in rat cerebral ischaemia: pharmacokinetics, distribution, protection. Br J Pharmacol (2010) 1.10
Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study. J Cereb Blood Flow Metab (2010) 1.08
Biodistribution, pharmacokinetics and metabolism of interleukin-1 receptor antagonist (IL-1RA) using [¹⁸F]-IL1RA and PET imaging in rats. Br J Pharmacol (2011) 1.07
The serum and cerebrospinal fluid pharmacokinetics of anakinra after intravenous administration to non-human primates. J Neuroimmunol (2010) 0.93
Population pharmacokinetic-pharmacodynamic-disease progression model for effects of anakinra in Lewis rats with collagen-induced arthritis. J Pharmacokinet Pharmacodyn (2011) 0.87
The role of inflammation and interleukin-1 in acute cerebrovascular disease. J Inflamm Res (2013) 0.84
Acute neuroimmune modulation attenuates the development of anxiety-like freezing behavior in an animal model of traumatic brain injury. J Neurotrauma (2012) 0.81
Blocking IL-1beta to slow down progression of ALS? Proc Natl Acad Sci U S A (2010) 0.79
Cell therapy centered on IL-1Ra is neuroprotective in experimental stroke. Acta Neuropathol (2016) 0.78
Reversal of established traumatic brain injury-induced, anxiety-like behavior in rats after delayed, post-injury neuroimmune suppression. J Neurotrauma (2013) 0.77
Intranasal Administration of Interleukin-1 Receptor Antagonist in a Transient Focal Cerebral Ischemia Rat Model. Biomol Ther (Seoul) (2017) 0.75
Pharmacokinetic(s) matters: stroke treatment et cetera. Br J Clin Pharmacol (2008) 0.75
Assessment of coma and impaired consciousness. A practical scale. Lancet (1974) 39.76
FUNCTIONAL EVALUATION: THE BARTHEL INDEX. Md State Med J (1965) 38.57
Interobserver agreement for the assessment of handicap in stroke patients. Stroke (1988) 20.14
Ischemic cell death in brain neurons. Physiol Rev (1999) 8.01
Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery (1980) 5.59
Interleukin-1 and neuronal injury. Nat Rev Immunol (2005) 3.85
A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry (2005) 2.41
Interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat. Brain Res Bull (1992) 1.80
A general conceptual model for non-steady state pharmacokinetic/pharmacodynamic data. J Pharmacokinet Biopharm (1995) 1.73
Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine (1992) 1.63
Inflammation in central nervous system injury. Philos Trans R Soc Lond B Biol Sci (2003) 1.56
The role of interleukin 1 in acute neurodegeneration and stroke: pathophysiological and therapeutic implications. J Clin Invest (1997) 1.48
Adventures in the pathophysiology of brain ischemia: penumbra, gene expression, neuroprotection: the 2002 Thomas Willis Lecture. Stroke (2003) 1.45
Potential mechanisms of interleukin-1 involvement in cerebral ischaemia. J Neuroimmunol (1999) 1.39
Blood-borne interleukin-1 receptor antagonist crosses the blood-brain barrier. J Neuroimmunol (1994) 1.38
Interleukin-1 receptor antagonist penetrates human brain at experimentally therapeutic concentrations. J Cereb Blood Flow Metab (2007) 1.34
Peripheral administration of Interleukin-1 Receptor antagonist inhibits brain damage after focal cerebral ischemia in the rat. Exp Neurol (1996) 1.28
The interleukin-1 receptor antagonist (rhIL-1ra) protects against cerebral infarction in a rat model of hypoxia-ischemia. Exp Neurol (1994) 1.20
Measurement of cerebrospinal fluid flow at the cerebral aqueduct by use of phase-contrast magnetic resonance imaging: technique validation and utility in diagnosing idiopathic normal pressure hydrocephalus. Neurosurgery (2002) 1.13
The use of microdialysis in CNS drug delivery studies. Pharmacokinetic perspectives and results with analgesics and antiepileptics. Adv Drug Deliv Rev (2000) 1.07
Interleukins and cerebral ischaemia. Int Rev Neurobiol (1997) 1.02
Pharmacokinetics of anakinra in subjects with different levels of renal function. Clin Pharmacol Ther (2003) 0.89
Blood-brain barrier integrity in patients with cerebral infarction investigated by computed tomography and serum-CSF-albumin. Acta Neurol Scand (1981) 0.82
Cerebrospinal fluid production in subarachnoid haemorrhage. Br J Neurosurg (1988) 0.80
The role of inflammation in CNS injury and disease. Br J Pharmacol (2006) 3.96
Interleukin-1 and neuronal injury. Nat Rev Immunol (2005) 3.85
Acute ischaemic stroke and infection: recent and emerging concepts. Lancet Neurol (2008) 2.77
Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clin Pharmacol Ther (2006) 2.72
Cleavage of the plasma membrane Na+/Ca2+ exchanger in excitotoxicity. Cell (2005) 2.63
Systemic inflammatory stimulus potentiates the acute phase and CXC chemokine responses to experimental stroke and exacerbates brain damage via interleukin-1- and neutrophil-dependent mechanisms. J Neurosci (2007) 2.47
Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol (2004) 2.30
Systemic inflammation alters the kinetics of cerebrovascular tight junction disruption after experimental stroke in mice. J Neurosci (2008) 2.21
An early and sustained peripheral inflammatory response in acute ischaemic stroke: relationships with infection and atherosclerosis. J Neuroimmunol (2003) 1.97
Development of a whole body physiologically based model to characterise the pharmacokinetics of benzodiazepines. 1: Estimation of rat tissue-plasma partition ratios. J Pharmacokinet Pharmacodyn (2004) 1.96
Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci (2005) 1.95
Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci (2006) 1.85
Caspase-1-dependent processing of pro-interleukin-1beta is cytosolic and precedes cell death. J Cell Sci (2007) 1.80
Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Stroke (2014) 1.77
Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses (2003) 1.67
CNS injury: the role of the cytokine IL-1. Vet J (2004) 1.65
Bridging the efficacy-effectiveness gap: a regulator's perspective on addressing variability of drug response. Nat Rev Drug Discov (2011) 1.58
Inflammation and infection in clinical stroke. J Cereb Blood Flow Metab (2002) 1.58
Inflammation in central nervous system injury. Philos Trans R Soc Lond B Biol Sci (2003) 1.56
Priming of macrophages with lipopolysaccharide potentiates P2X7-mediated cell death via a caspase-1-dependent mechanism, independently of cytokine production. J Biol Chem (2001) 1.52
Delayed administration of interleukin-1 receptor antagonist protects against transient cerebral ischaemia in the rat. Br J Pharmacol (2003) 1.50
Brain inflammation is induced by co-morbidities and risk factors for stroke. Brain Behav Immun (2011) 1.44
Different photoperiods affect proliferation of lymphocytes but not expression of cellular, humoral, or innate immunity in hamsters. J Biol Rhythms (2002) 1.40
Ca2+ stores and Ca2+ entry differentially contribute to the release of IL-1 beta and IL-1 alpha from murine macrophages. J Immunol (2003) 1.39
Difficulties with recruiting into neurosurgical clinical trials: the Surgical Trial in IntraCerebral Haemorrhage II as an example. Br J Neurosurg (2011) 1.39
Platelet interleukin-1alpha drives cerebrovascular inflammation. Blood (2010) 1.38
Inflammation in human brain injury: intracerebral concentrations of IL-1alpha, IL-1beta, and their endogenous inhibitor IL-1ra. J Neurotrauma (2007) 1.36
Interleukin-1 receptor antagonist penetrates human brain at experimentally therapeutic concentrations. J Cereb Blood Flow Metab (2007) 1.34
Interleukin-1-induced neurotoxicity is mediated by glia and requires caspase activation and free radical release. J Neurochem (2006) 1.27
A rapid and transient peripheral inflammatory response precedes brain inflammation after experimental stroke. J Cereb Blood Flow Metab (2009) 1.22
Associations between the organisation of stroke services, process of care, and mortality in England: prospective cohort study. BMJ (2013) 1.20
Delayed administration of interleukin-1 receptor antagonist reduces ischemic brain damage and inflammation in comorbid rats. J Cereb Blood Flow Metab (2012) 1.20
Factors influencing non-approval of new drugs in Europe. Nat Rev Drug Discov (2012) 1.18
Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm Res (2007) 1.18
Interleukin-1 and stroke: biomarker, harbinger of damage, and therapeutic target. Cerebrovasc Dis (2011) 1.18
A dual role for interleukin-1 in LTP in mouse hippocampal slices. J Neuroimmunol (2003) 1.17
Regulation of interleukin-1 in acute brain injury. Trends Pharmacol Sci (2011) 1.15
Euglycemic hyperinsulinemia augments the cytokine and endocrine responses to endotoxin in humans. Am J Physiol Endocrinol Metab (2002) 1.14
Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J Neurosci (2003) 1.14
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance. J Pharm Sci (2011) 1.14
Innovations in major system reconfiguration in England: a study of the effectiveness, acceptability and processes of implementation of two models of stroke care. Implement Sci (2013) 1.14
Neutrophil cerebrovascular transmigration triggers rapid neurotoxicity through release of proteases associated with decondensed DNA. J Immunol (2012) 1.10
Rapid brain penetration of interleukin-1 receptor antagonist in rat cerebral ischaemia: pharmacokinetics, distribution, protection. Br J Pharmacol (2010) 1.10
Expression of interleukin-1 receptors and their role in interleukin-1 actions in murine microglial cells. J Neurochem (2002) 1.09
Predicting aspiration after hemispheric stroke from timing measures of oropharyngeal bolus flow and laryngeal closure. Dysphagia (2009) 1.09
Interleukin-1 receptor antagonist is beneficial after subarachnoid haemorrhage in rat by blocking haem-driven inflammatory pathology. Dis Model Mech (2012) 1.09
Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study. J Cereb Blood Flow Metab (2010) 1.08
Experimental stroke-induced changes in the bone marrow reveal complex regulation of leukocyte responses. J Cereb Blood Flow Metab (2010) 1.08
Increased brain microvascular MMP-9 and incidence of haemorrhagic transformation in obese mice after experimental stroke. J Cereb Blood Flow Metab (2009) 1.06
Role of P2X7 receptors in ischemic and excitotoxic brain injury in vivo. J Cereb Blood Flow Metab (2003) 1.06
Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures. J Neurosci Res (2002) 1.06
Neuroprotective actions of endogenous interleukin-1 receptor antagonist (IL-1ra) are mediated by glia. Glia (2006) 1.06
Microglia and macrophages differentially modulate cell death after brain injury caused by oxygen-glucose deprivation in organotypic brain slices. Glia (2013) 1.05
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution. J Pharm Sci (2011) 1.04
Inflammation in acute ischemic stroke and its relevance to stroke critical care. Neurocrit Care (2008) 1.04
PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach. J Pharm Sci (2011) 1.03
Poststroke shoulder pain: a prospective study of the association and risk factors in 152 patients from a consecutive cohort of 205 patients presenting with stroke. Eur J Pain (2002) 1.02
Neuronal Toll-like receptor 4 signaling induces brain endothelial activation and neutrophil transmigration in vitro. J Neuroinflammation (2012) 1.02
Clinical outcome following acute ischaemic stroke relates to both activation and autoregulatory inhibition of cytokine production. BMC Neurol (2007) 1.02
[18F]DPA-714: direct comparison with [11C]PK11195 in a model of cerebral ischemia in rats. PLoS One (2013) 1.00
Classification of minor stroke: intra- and inter-observer reliability. Cerebrovasc Dis (2009) 1.00
Purinergic (P2X7) receptor activation of microglia induces cell death via an interleukin-1-independent mechanism. Mol Cell Neurosci (2002) 1.00
Accuracy and clinical usefulness of intracerebral hemorrhage grading scores: a direct comparison in a UK population. Stroke (2013) 0.99
Matrix metalloproteinase-9 and urokinase plasminogen activator mediate interleukin-1-induced neurotoxicity. Mol Cell Neurosci (2007) 0.98
Integrin-binding RGD peptides induce rapid intracellular calcium increases and MAPK signaling in cortical neurons. Mol Cell Neurosci (2006) 0.98
Efficient discovery of anti-inflammatory small-molecule combinations using evolutionary computing. Nat Chem Biol (2011) 0.97
Differential effects of interleukin-1 alpha and beta on interleukin-6 and chemokine synthesis in neurones. Mol Cell Neurosci (2008) 0.96
Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. Eur J Pharm Sci (2010) 0.96
Variability of the systemic acute phase response after ischemic stroke. J Neurol Sci (2006) 0.95
Leptin induces interleukin-1beta release from rat microglial cells through a caspase 1 independent mechanism. J Neurochem (2007) 0.95
Regulation of expression of the novel IL-1 receptor family members in the mouse brain. J Neurochem (2005) 0.94
The use of isotopes in the determination of absolute bioavailability of drugs in humans. Expert Opin Drug Metab Toxicol (2006) 0.93
Cerebrospinal fluid and plasma cytokines after subarachnoid haemorrhage: CSF interleukin-6 may be an early marker of infection. J Neuroinflammation (2012) 0.93
Involvement of caspases and calpains in cerebrocortical neuronal cell death is stimulus-dependent. Br J Pharmacol (2002) 0.92
Diazepam pharamacokinetics from preclinical to phase I using a Bayesian population physiologically based pharmacokinetic model with informative prior distributions in WinBUGS. J Pharmacokinet Pharmacodyn (2006) 0.92
No role for interleukin-18 in acute murine stroke-induced brain injury. J Cereb Blood Flow Metab (2003) 0.92